Sheila Gujrathi - 25 Oct 2021 Form 4 Insider Report for Ventyx Biosciences, Inc. (VTYX)

Role
Director
Signature
/s/ Christopher Krueger, as Attorney-in-Fact
Issuer symbol
VTYX
Transactions as of
25 Oct 2021
Net transactions value
$0
Form type
4
Filing time
25 Oct 2021, 18:45:37 UTC
Previous filing
20 Oct 2021
Next filing
03 Dec 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VTYX Common Stock Conversion of derivative security $0 +32,897 $0.000000 32,897 25 Oct 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VTYX Series A Preferred Stock Conversion of derivative security $0 -32,897 -100% $0.000000* 0 25 Oct 2021 Common Stock 32,897 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 All shares of the preferred stock, par value $0.0001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.